Cardiometabolic & kidney

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

JAMA CardiolPublished prespecified secondary analysis of the double-blind, placebo-controlled, event-driven, phase 3b SOUL randomized clinical trial

Primary result · Total (first and subsequent) 3-P MACEResult — go to the resultMean ratio 0.86 95% CI 0.76–0.97

Authors' conclusion

Oral semaglutide reduced the risk of first plus subsequent 3-P MACE vs placebo, highlighting the benefit of oral semaglutide in reducing the total burden of clinical morbidity and mortality in this high-risk population.

Study context

Population
Participants with type 2 diabetes and atherosclerotic CV disease and/or chronic kidney diseaserandomized 1:1, median (IQR) follow-up 49.5 (44.0–54.9) months
Participants
9,650 participants
Comparison
Oral semaglutide vs placebo
Primary endpoint
Total (first and subsequent) 3-P MACE
Methodological details444 centers in 33 countries
  • 444 centers in 33 countries

Primary result

Total (first and subsequent) 3-P MACE

Mean ratio

0.86

95% CI 0.76–0.97

P = 0.01

Events by treatment group

Oral semaglutide

683 total; 579 first and 104 subsequent events

events

Placebo

791 total; 668 first and 123 subsequent events

events

As reported in the abstract

Further findings

Events events

OutcomeOral semaglutidePlaceboMean ratio (95% CI)P value
Total 3-P MACE plus non-CV death91010480.87 (0.79–0.95)P = 0.004
Total 3-P MACE plus non-CV death — Fewer total events with oral semaglutide
138

Safety

Adverse events leading to treatment discontinuation · As previously reported

Original publication

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA Cardiol. Published 11 November 2026. doi:10.1001/jamacardio.2026.4944

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.